Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Charles Dinarello to alpha-Synuclein

This is a "connection" page, showing publications Charles Dinarello has written about alpha-Synuclein.

 
Connection Strength
 
 
 
0.426
 
  1. Luque M, Matic M, Heras-Garvin A, Amo-Aparicio J, Luk KC, Haindl MT, Khalil M, Skouras DB, Dinarello CA, Stefanova N. Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates a-synuclein-induced progression of parkinsonism. J Neuroinflammation. 2026 Jan 31; 23(1).
    View in: PubMed
    Score: 0.232
  2. Amo-Aparicio J, Daly J, Højen JF, Dinarello CA. Pharmacologic inhibition of NLRP3 reduces the levels of a-synuclein and protects dopaminergic neurons in a model of Parkinson's disease. J Neuroinflammation. 2023 Jun 22; 20(1):147.
    View in: PubMed
    Score: 0.194
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)